E Michael Lewiecki1. 1. New Mexico Clinical Research & Osteoporosis Center, 300 Oak St. NE, Albuquerque, NM, 87106, USA. mlewiecki@gmail.com.
Abstract
PURPOSE OF REVIEW: This review provides suggestions for the evaluation of patients with osteoporosis in order to assure that the diagnosis is correct, to identify potentially correctable conditions contributing to skeletal fragility and fracture risk, and to assist in individualizing management decisions. RECENT FINDINGS: Some patients who appear to have osteoporosis have another skeletal disease, such as osteomalacia, that requires further evaluation and treatment that is different than for osteoporosis. Many patients with osteoporosis have contributing factors (e.g., vitamin D deficiency, high fall risk) that should be addressed before and after starting treatment to assure that treatment is effective and safe. Evaluation includes a focused medical history, skeletal-related physical examination, assessment of falls risk, appropriate laboratory tests, and rarely transiliac double-tetracycline labeled bone biopsy. Evaluation of patients with osteoporosis before starting treatment is essential for optimizing clinical outcomes.
PURPOSE OF REVIEW: This review provides suggestions for the evaluation of patients with osteoporosis in order to assure that the diagnosis is correct, to identify potentially correctable conditions contributing to skeletal fragility and fracture risk, and to assist in individualizing management decisions. RECENT FINDINGS: Some patients who appear to have osteoporosis have another skeletal disease, such as osteomalacia, that requires further evaluation and treatment that is different than for osteoporosis. Many patients with osteoporosis have contributing factors (e.g., vitamin D deficiency, high fall risk) that should be addressed before and after starting treatment to assure that treatment is effective and safe. Evaluation includes a focused medical history, skeletal-related physical examination, assessment of falls risk, appropriate laboratory tests, and rarely transiliac double-tetracycline labeled bone biopsy. Evaluation of patients with osteoporosis before starting treatment is essential for optimizing clinical outcomes.
Authors: Roger A L Sutton; Steven Mumm; Stephen P Coburn; Karen L Ericson; Michael P Whyte Journal: J Bone Miner Res Date: 2012-05 Impact factor: 6.741
Authors: Christopher R Shuhart; Swan Sim Yeap; Paul A Anderson; Lawrence G Jankowski; E Michael Lewiecki; Leslie R Morse; Harold N Rosen; David R Weber; Babette S Zemel; John A Shepherd Journal: J Clin Densitom Date: 2019-07-05 Impact factor: 2.617
Authors: J A Kanis; D Hans; C Cooper; S Baim; J P Bilezikian; N Binkley; J A Cauley; J E Compston; B Dawson-Hughes; G El-Hajj Fuleihan; H Johansson; W D Leslie; E M Lewiecki; M Luckey; A Oden; S E Papapoulos; C Poiana; R Rizzoli; D A Wahl; E V McCloskey Journal: Osteoporos Int Date: 2011-07-21 Impact factor: 4.507
Authors: E S Siris; R Adler; J Bilezikian; M Bolognese; B Dawson-Hughes; M J Favus; S T Harris; S M Jan de Beur; S Khosla; N E Lane; R Lindsay; A D Nana; E S Orwoll; K Saag; S Silverman; N B Watts Journal: Osteoporos Int Date: 2014-02-28 Impact factor: 4.507
Authors: Alice Costantini; Riikka E Mäkitie; Markus A Hartmann; Nadja Fratzl-Zelman; M Carola Zillikens; Uwe Kornak; Kent Søe; Outi Mäkitie Journal: J Bone Miner Res Date: 2022-09-11 Impact factor: 6.390